Acurx Pharmaceuticals, Inc. — Director's Dealing 2021

Jul 6, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Acurx Pharmaceuticals, Inc. (ACXP)
CIK: 0001736243
Period of Report: 2021-06-29

Reporting Person: LUCI DAVID P (Director, President and CEO, 10% Owner)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-29	Stock Option	$6.26	A	350000	Acquired	2031-06-28	Common Stock (350000)	Direct
2021-07-01	Stock Option	$6.18	A	500000	Acquired	2031-06-30	Common Stock (500000)	Direct

Footnotes

F1: On June 29, 2021 (the "June Grant Date"), the Reporting Person was granted stock options to purchase 350,000 shares of the Issuer's common stock. 40% of the stock options granted became vested and exercisable on the June Grant Date and 60% of the stock options shall become vested and exercisable as of each monthly anniversary from the June Grant Date, such that all stock options shall be fully vested and exercisable by June 29, 2024. This transaction is late due to an inadvertent administrative error and not any error of the Reporting Person.

F2: On July 1, 2021 (the "Employment Agreement Grant Date"), the Reporting Person was granted stock options to purchase 500,000 shares of the Issuer's common stock in connection with the Reporting Person's service as the Issuer's President and Chief Executive Officer pursuant to the Reporting Person's employment agreement. 25% of the stock options granted became vested and exercisable on the Employment Agreement Grant Date and 75% of the stock options shall become vested and exercisable as of each monthly anniversary from the Employment Agreement Grant Date, such that all stock options shall be fully vested and exercisable by July 1, 2024.